Year All202620252024202320222021202020192018201720162015201420122011 Mar 12, 2026 Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award Mar 9, 2026 Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C Mar 4, 2026 Ardelyx to Participate in Upcoming Investor Conferences Feb 24, 2026 Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions Feb 19, 2026 Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Feb 5, 2026 Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 Feb 3, 2026 Ardelyx Receives New Patent for Tenapanor Jan 28, 2026 First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA Jan 8, 2026 Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook Nov 7, 2025 Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week